• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Pharmacological inactivation of AKT/ERK and β-Catenin by 7-difluoromethoxyl-5,4'-di-n-octyl gen

Pharmacological inactivation of AKT/ERK and β-Catenin by 7-difluoromethoxyl-5,4'-di-n-octyl gen

来源 :第四届广州国际肿瘤学会议 | 被引量 : 0次 | 上传用户：nkivy
【摘 要】
：
The epithelial-mesenchymal transition(EMT)has been shown to induce cancer stem traits.However,pharma-therapeutic approach to simultaneously prevent EMT and cancer stemness is lacking.
【作 者】
：
Yingxia Ning Dalmira Merzhakupova Madina Satayeva Liangsheng Fan Xiaowei Zhang Juhong Jiang 
【机 构】
：
Department of Gynaecology and Obstetrics,The First Affiliated Hospital of Guangzhou Medical College,
【出 处】
：
第四届广州国际肿瘤学会议
【发表日期】
：
2015年7期
【关键词】
：
The epithelial-mesenchymal transition (EMT) cancer stem cell DFOG 
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　The epithelial-mesenchymal transition(EMT)has been shown to induce cancer stem traits.However,pharma-therapeutic approach to simultaneously prevent EMT and cancer stemness is lacking.
其他文献
CXCL2/MIF/CXCR2 axis-mediated myeloid-derived suppressor cells recruitment regulate tumor progressio
Myeloid-derived suppressor cell(MDSC)expansion in tumor-bearing host is correlated with immune suppression; however its related mechanism is still largely blurred.
会议
Exosomaldelivery of miR-24-3pmediates T-cell dysfunction viarepressing FGF11 and correlates with pro
Tumor-derived exosomes(T-EXO)carry a broad range of cargo,including proteins,microRNAs,mRNAs,and DNA fragments,to transfer signaling between tumor cell and immune cells.
会议
Inhibition of c-FLIP by RNAi augments TRAIL-induced apoptosis in human osteosarcoma cells
Introduction: Elevated c-FLIP levels which are observed in many cancers,were also shown to correlate with a more aggressive tumor.
会议
c-FLIPRNA interferenceTRAILosteogenic sarcomaU2OS cells
Isoform-specific regulation of AKT turn-motif phosphorylation and overall phosphorylation profiles
Aberrant AKT activation is prevalent across multiple human cancer lineages,providing an important target for therapy.Phosphorylation plays critical roles in AKT stability and activation.
会议
AKTturn-motifphosphorylationIsoform-specific
Validation of progression-free survival as a surrogate endpoint for overall survival in malignant me
To investigate whether progression-free survival(PFS)can be considered a surrogate endpoint for overall survival(OS)in malignant mesothelioma both at the patient and trial level.
会议
Non-invasive fibrosis indexes in predicting acute liver function deterioration after Transcatheter a
Background Transcatheter arterial chemoembolization(TACE)is the first-line therapy for unresectable Hepatocellular Carcinoma(HCC),acute liver function deterioration(ALFD)after operation is a severe co
会议
AST to PLT ratio index (APRI)FIB-4Transcatheter arterial chemoembolization (TA
Efficacy and security of treatment by bevacizumab and platinum-based on chemotherapy on advanced non
Objective: To evaluate efficacy and security of treatment by bevacizumab and platinum on advanced nonsmall-cell lung cancer.
会议
bevacizumablung neoplasmsplatinumchemotherapyMeta analysis
New progress in the study of bevacizumab combined with chemotherapy in the treatment of lung cancer
Objective: Summary of the latest progress of bevacizumab combined with chemotherapy in the treatment of lung cancer in recent 4 years.
会议
bevacizumablung neoplasmachemotherapyprogress
The mechanism of bevacizumab combined with cisplatin interfer the invasion and metastasis of lung ad
Objective: Research on the mechanism of bevacizumab combined with cisplatin inhibits the invasion and metastasis of Lewis lung adenocarcinoma.
会议
bevacizumabcisplatinlung neoplasmavascular endothelial growth factorbasic fi
Randomized effects of five platinum-based chemotherapy regimens in the first treatment of advanced N
OBJECTIVE: To observe efficacy and security of five chemotherapeutic schemes including platinum on advanced nonsmall-cell lung cancer.
会议
cisplatinchemotherapylung neoplasmsNSCLCnon-small cell lung cancerefficacy